El estudio liderado por investigadores\/as del Instituto Catal\u00e1n de Oncolog\u00eda (ICO), el Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL), el Instituto de Investigaci\u00f3n Germans Trias i Pujol (IGTP), y el Translational Genomics Research Institute de Estados Unidos, se ha publicado en la revista ‘Genome Medicine<\/strong><\/a>‘ y representa un paso significativo hacia una mejor comprensi\u00f3n de c\u00f3mo las alteraciones en el sistema inmunol\u00f3gico facilitan la aparici\u00f3n del c\u00e1ncer.<\/p>\n
Por el responsable del estudio y jefe del Programa ProCURE del ICO, Miquel \u00c0ngel Pujana<\/a>, tambi\u00e9n investigador del IDIBELL: \u201cEste estudio abre nuevas v\u00edas para la mejora de la prevenci\u00f3n del c\u00e1ncer de forma personalizada, y los hallazgos podr\u00edan conducir a estrategias preventivas m\u00e1s espec\u00edficas, adaptadas a las caracter\u00edsticas gen\u00e9ticas individuales<\/strong>\u201d.<\/p>\n
El Dr. Rafael de Cid, co-responsable del estudio y jefe del proyecto GCAT!Genomes for Life- IGTP, destaca la complejidad y la interconexi\u00f3n de la arquitectura del genoma humano: \u201cLa investigaci\u00f3n gen\u00e9tica centrada en rasgos biol\u00f3gicos medibles, sencillos, puede ser una v\u00eda para entender las bases gen\u00e9ticas de rasgos m\u00e1s complejos, como el c\u00e1ncer<\/strong>\u201d.<\/p>\n
En resumen, los autores subrayan la importancia del progreso en la investigaci\u00f3n gen\u00e9tica para mejorar la prevenci\u00f3n y tratamiento del c\u00e1ncer, hacia una personalizaci\u00f3n de estas intervenciones.<\/p>\n
Los primeros coautores del trabajo son Miguel Angel Pardo (ICO-IDIBELL, programa PERIS-Salut), Xavier Farr\u00e9 (GCAT), Anna Esteve (ICO-IGTP), Joanna Palade (TGen) y Roderic Esp\u00edn (ICO-IDIBELL, programa PERIS-Salud).<\/p>\n
<\/p>\n
<\/p>\n
<\/p>\n
El Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) es un centro de investigaci\u00f3n en biomedicina creado en 2004. Est\u00e1 participado por el Hospital Universitario de Bellvitge y el Hospital de Viladecans del Instituto Catal\u00e1n de la Salud, l Instituto Catal\u00e1n de Oncolog\u00eda, la Universidad de Barcelona y el Ayuntamiento de Hospitalet de Llobregat.<\/span><\/i>\u00a0<\/span><\/p>\n
IDIBELL es miembro del Campus de Excelencia Internacional de la Universidad de Barcelona HUBc y forma parte de la instituci\u00f3n CERCA de la Generalitat de Catalunya. En 2009 se convirti\u00f3 en uno de los cinco primeros centros de investigaci\u00f3n espa\u00f1oles acreditados como instituto de investigaci\u00f3n sanitaria por el Instituto de Salud Carlos III. Adem\u00e1s, forma parte del programa \u00abHR Excellence in Research\u00bb de la Uni\u00f3n Europea y es miembro de EATRIS y REGIC. Desde 2018, el IDIBELL es un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/span><\/i>\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"
Un equipo internacional de investigadores identifica la base gen\u00e9tica y los procesos biol\u00f3gicos que influyen en el riesgo de c\u00e1ncer relacionado con alteraciones en el n\u00famero de c\u00e9lulas inmunol\u00f3gicas presentes en sangre.<\/p>\n","protected":false},"author":8,"featured_media":23834,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,292,371,281],"tags":[],"class_list":["post-23833","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-cancer","category-cancer-de-mama-cancer-2","category-procure","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2025-04-12 11:57:55","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23833","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=23833"}],"version-history":[{"count":3,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23833\/revisions"}],"predecessor-version":[{"id":23839,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/23833\/revisions\/23839"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/23834"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=23833"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=23833"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=23833"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}